Massachusetts Medical Society: Question 9

Question 9

 

Question:

 

Compared with clopidogrel (Plavix), prasugrel (Effient) has been shown to reduce the risk of cardiovascular events in acute coronary syndromes patients who do not undergo percutaneous coronary intervention.

 

 

 

Answers

Answer:

True
 

 

Correct Answer? 

 

Explanation:

 

Answers

Answer:

False
 

 

Correct Answer? 

 

Explanation:

Best answer:  False. The TRILOGY-ACS trial compared prasugrel plus aspirin to clopidogrel plus aspirin in patients with acute coronary syndromes who did not have percutaneous coronary intervention or other procedures.  The study found no significant benefit of combining prasugrel with aspirin in reducing the rate of cardiovascular death, myocardial infarction, or stroke over 30 months, compared to the clopidogrel-aspirin arm.

 

 

Format:

Radio buttons (single select)

 

Share on Facebook
Facebook logoLinkedInYouTube logoInstagramThreads

Copyright © 2025. Massachusetts Medical Society, 860 Winter Street, Waltham Woods Corporate Center, Waltham, MA 02451-1411

(781) 893-4610 | General Support: (617) 841-2925 or support@mms.org